Image For Activity Cover
Project ECHO: Approaches to Long-Term Weight Loss and Obesity Care
Course Description
Open to all clinicians, this program seeks to educate primary care providers, care teams, and non-obesity specialists in best practices in obesity care and management. With many therapeutic and pharmacological options available, clinicians need additional resources to stay up-to-date in obesity management. This program, featuring live, interactive seminars and on-demand webinars, will focus on evidence-based methods for addressing obesity and managing its comorbidities in a compassionate manner, with a goal of ending stigma and improving health-related quality-of-life for patients. The aim is to address the obesity epidemic and associated diseases by educating clinicians around the world in best-practices and research directly from obesity-management specialists. There will be a total of 12 ECHOs throughout the next year, each focusing on a different aspect of obesity and associated comorbidities.

Project ECHO started at the University of New Mexico in 2003. ECHO stands for Extension of Community Healthcare Outcomes, and it is built on the idea that while not everyone can be a specialist, all patients deserve access to specialty care. Using a hub and spoke model, and virtual platforms like Zoom, specialists are able to connect with non-specialist providers in real time to provide education and feedback on cases. Our ECHOs, which will focus on the management of obesity, will be held on a monthly basis as live and on-demand webinars.

This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.
Target Audience
This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, obesity and associated diseases. Additionally, this program may be of interest to primary care professionals and advance practice professionals who treat patients with obesity.
Learning Objectives

Upon completing this series, learners will be able to:

  1. Identify new and emerging trends in obesity medicine and management;
  2. Identify and review available and emerging therapeutic approaches to obesity management;
  3. Review different approaches to weight loss/maintenance.
Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
Faculty and Disclosures

The core faculty for Project ECHO: Approaches to Long-Term Weight Loss and Obesity Care are:

Amy E. Rothberg, MD, PhD - Program Chair
University of Michigan 

Jamy Ard, MD
Wake Forest School of Medicine 

Donna H. Ryan, MD
Pennington Biomedical Research Center

Jonathan Purnell, MD
Oregon Health and Science University

Beret A. Casey, MD - Peer Reviewer
Essentia Health

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following faculty reported relevant financial relationships: Amy E. Rothberg, MD, PhD - Self: Rhythm, Consultant/Advisory; Spouse: Merck, Data Safety Monitoring Board. Jonathan Purnell, MD - Self: Novo Nordisk, Advisor Board - Global Obesity Program. Jamy Ard, MD - Self: Novo Nordisk, UnitedHealth Group, Boehringer-Ingelheim, Nestle Healthcare Nutrition, Consultant; Epitomee Medical, Research Grant. Donna H. Ryan, MD - Self: Alyvent, Bausch Health, Boeringer Ingelheim, Epitomee, Janssen, Novo Nordisk, real appeal (United Health), ReDesign Health, and Sanofi - Consulting Fee. Self: Novo Nordisk, Bausch Health - Speakers Bureau. Self: Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake - Ownership Interest. Self: SELECT Steering Committee (Novo Nordisk) - Research.

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewer reported no relevant financial relationships: Beret A. Casey, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.
Summary
Availability: On-Demand
Available Jul 06, 2020 to Dec 31, 2023
Cost : FREE
Credit Offered:
12 AMA PRA Category 1 Credits
12 Participation Credits
Contains: 12 Courses
Recommended
   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Powered By